Ardelyx and AstraZeneca's tenapanor fails to meet primary endpoint in Phase IIa study

6 May 2015

Biopharma company Ardelyx (Nasdaq: ARDX) announced that its Phase IIa trial of tenapanor in kidney disease with diabetes did not meet its primary endpoint.

Tenapanor’s development and commercialization is being carried out by Ardelyx in partnership with AstraZeneca (LSE: AZN). The Phase IIa trial evaluated the drug in stage 3 chronic kidney disease patients with type 2 diabetes mellitus and albuminuria, and did not meet the primary endpoint of decreasing the urinary albumin-creatinine ratio in tenapanor-treated patients, compared to patients receiving placebo.

The drug has been evaluated in over 1,000 patients as part of 14 clinical trials in healthy volunteers and patients with constipation-predominant irritable bowel syndrome, hyperphosphatemia and chronic kidney disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK